CompletedNot Applicable

EVALUATION of GINGIVAL CREVICULAR FLUID and SERUM ASPROSIN LEVELS in OBESE and NORMAL-WEIGHT INDIVIDUALS with PERIODONTITIS

Turkey (Türkiye)60 participantsStarted 2023-08-08

Plain-language summary

Obesity and periodontitis are chronic inflammatory diseases that share common pathological mechanisms. Asprosin, a novel adipokine discovered in 2016, has not been extensively studied in relation to periodontal tissues. In our study, we investigate the levels of asprosin in both serum and gingival crevicular fluid of patients with obesity and those of normal weight who have periodontitis. Additionally, our research aims to clarify the pathophysiological mechanisms linking periodontitis and obesity by examining local and systemic levels of TNF-α, IL-6, and asprosin, alongside clinical periodontal parameters.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Willingness to participate in the study.
✓. Weight classification:
✓. Periodontal health status:
✓. For individuals with periodontitis:

Exclusion criteria

✕. Individuals who have received periodontal therapy, any oral decontamination treatment, or antibiotics or steroids in the six months prior to the start of the study.
✕. Individuals who are pregnant or breastfeeding.
✕. Individuals diagnosed with rheumatoid arthritis or lupus erythematosus.
✕. Individuals with a medical history of radiation or cancer therapy.
✕. Patients with diabetes, defined by:
✕. Smokers.

What they're measuring

Biyomarker levels

Timeframe: 08.10.2023-08.10.2024

Trial details

NCT IDNCT06879951

SponsorGazi University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08-10

View on ClinicalTrials.gov More Periodontitis trials